Targeted delivery of doxorubicin to HER2 positive tumor models
Hosna Gomari,1 Mehdi Forouzandeh Moghadam,1 Masoud Soleimani,2 Mahlegha Ghavami,1 Shabanali Khodashenas31Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran; 2Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Teh...
Guardado en:
Autores principales: | Gomari H, Forouzandeh Moghadam M, Soleimani M, Ghavami M, Khodashenas S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fd607917721945adb0d2a9ef99ae6bfa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeted Delivery Of Doxorubicin To HER2 Positive Tumor Models [Corrigendum]
por: Gomari H, et al.
Publicado: (2019) -
Aptamer–drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity
por: Dou XQ, et al.
Publicado: (2018) -
CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells
por: Jiang S, et al.
Publicado: (2016) -
Novel functionalized nanoparticles for tumor-targeting co-delivery of doxorubicin and siRNA to enhance cancer therapy
por: Xia Y, et al.
Publicado: (2017) -
Mesenchymal stem cell exosomes: a two-edged sword in cancer therapy
por: Vakhshiteh F, et al.
Publicado: (2019)